InvestCurb Visuals

Path to Financial Freedom.
On the road again
Retirement Life.

Stock Screener

BioPharm News Updates

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares are trading up +31%  to $0.38 during after-hours following the publication of an article in the peer-reviewed Journal of the American Heart Association addressing the role of NLRP3 inflammasomes in PAD. ZyVersa's Inflammasome ASC Inhibitor IC 100 inhibits the inflammasome adaptor protein ASC, a component of multiple types of inflammasomes including NLRP3 inflammasomes.

Owlet (NYSE: OWLT) announced clearance from the FDA of BabySat, the first medical pulse-oximetry device featuring its advanced, wire-free sock design. Shares closed up 54% at $0.35.

DICE Therapeutics, Inc. (NASDAQ: DICE) and Eli Lilly and Company (NYSE: LLY) signed a definitive agreement for Lilly to acquire DICE. Under the agreement, Lilly will commence a tender offer to acquire all outstanding shares of DICE for a purchase price of $48 per share in cash for approximately $2.4 billion payable at closing. Dice shares closed up 37% at $46.44.

Zura Bio (NASDAQ: ZURA) shares closed up 35% at $12.80 after recent news that Deep Track Capital LP reported a 9.39% passive stake in the company.

Leap Thearapeutics (NASDAQ: LPTX) shares closed down after the company effected a 10-for-1 reverse stock split. Shares closed down 23% at $0.52.

Arcellx, Inc. (NASDAQ: ACLX) announced that it has received notification from the FDA that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). The clinical hold was received on June 16, following a recent patient death. Shares closed down 7% at $33.23.

Evelo Biosciences (NASDAQ: EVLO) shares closed up 46% at $0.18 after a recent patent was granted for prebiotic compositions and methods of use thereof modulation of the microbiome.

Vera Therapeutics, Inc. (NASDAQ: VERA) reported that its Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36. Shares closed up 17% at $15.05.

Surgalign Holdings (NASDAQ: SRGA) shares closed down 82% at $0.22 following the filing of a voluntary Chapter 11 bankruptcy. The company‚Äôs bankruptcy estimates assets and liabilities in the range of $50 million to $100 million in the Bankruptcy Court for the Southern District of Texas.

Related Articles

Free Joomla! templates by AgeThemes